Primary Pleural Synovial Sarcoma Presenting as Small Nodules Hidden in Pleural Effusion

of hemorrhagic pleural effusion caused by PPSS and outline the step-by-step diagnosis and treatment procedure in this article. Further investigations are needed to determine the optimal treatment of PPSS. AbsTRACT Primary Pleural Synovial Sarcoma Present ing as Small Nodules Hidden in Pleural Effusion . This is a case report of a middle-aged woman presenting as recurrent hemorrhagic pleural effusion. The patient had only mild symptoms of pain. Pleural effusion examinations showed hemorrhagic exudate and other routine diagnostic methods including bronchoscopy, microbiological examinations, and cytopathology of pleural effusion could not identify the cause. PET-CT showed a metabolically active nodule in the pleural cavity. Over a 3-month period, chest CT showed recurrent pleural effusion with enlarged soft tissue. Several pleural neoplasms and obvious pleural congestion were seen under medical thoracoscopy. However, the specimen exhibited no evidence of malignancy with a medical thoracoscopy biopsy. After multidisciplinary team discussion, the patient underwent surgical thoracoscopy and had comprehensive pleural tumor resection. The pathological results of the surgical specimen showed pleural synovial sarcoma. The patient received chemotherapy with liposomal adriamycin and ifosfamide for five cycles after surgery. Regular follow-ups

This is a case report of a middle-aged woman presenting as recurrent hemorrhagic pleural effusion. The patient had only mild symptoms of pain. Pleural effusion examinations showed hemorrhagic exudate and other routine diagnostic methods including bronchoscopy, microbiological examinations, and cytopathology of pleural effusion could not identify the cause. PET-CT showed a metabolically active nodule in the pleural cavity. Over a 3-month period, chest CT showed recurrent pleural effusion with enlarged soft tissue. Several pleural neoplasms and obvious pleural congestion were seen under medical thoracoscopy. However, the specimen exhibited no evidence of malignancy with a medical thoracoscopy biopsy. After multidisciplinary team discussion, the patient underwent surgical thoracoscopy and had comprehensive pleural tumor resection. The pathological results of the surgical specimen showed pleural synovial sarcoma. The patient received chemotherapy with liposomal adriamycin and ifosfamide for five cycles after surgery. Regular follow-ups show that she is doing well. results showed a slight increase of platelet count(430×109/L), CA125(65.5IU/ml), ESR (70mm/H) and D-Dimer(343ng/ml). Chest contrast enhanced CT showed a small amount of pleural effusion on the right side ( Figure 1a). Bronchoscopy showed bronchitis and acid-fast staining of the protected specimen brush was negative.
Biopsy of bronchial mucosa showed chronic inflammation.
Thoracocentesis was performed and laboratory tests of pleural effusion showed the appearance was hemorrhagic. The cell counts were 4900/ul with 70% mononuclear cells and 30% multinuclear cells. RBC counts, total protein, LDH and ADA were 324000/ul, 61.8g/L, 1207U/L and 32U/L, respectively.

Discussion
Synovial sarcoma is a rare malignancy of mesenchymal origin which mostly affect adolescents and young adults [3]. Although any soft tissue may be involved, it commonly occurs near the joints of the extremities [4]. Synovial sarcoma can be classified as monophasic, biphasic, and poorly differentiated histologically [3]. Primary pleural synovial sarcoma (PPSS) is extremely rare which was first reported in 1996 [5]. The symptoms of PPSS are not distinctive, which may include chest pain, dyspnea and cough, and some patients were asymptomatic [6,7]. The most common radiographic findings are a well-circumscribed mass with effusion [6]. According to previous reports, PPSS are usually large in size without lymph nodes metastasis [4,[6][7][8]. While in the present case, the small lesion was masked by pleural effusion and was difficult to be detected by enhance CT. PET-CT is helpful in finding the tumor and evaluating the regions of involvement.
We believe that favorable outcome may be attributed to early diagnosis in this case. The diagnosis of PPSS is often difficult, as reported by Minoru Yamaki et al. [8] the specimen obtained from CT-guided needle biopsy may be not enough for accurate diagnosis. Medical thoracoscopy was also proved insufficient for diagnosis in our patient-most likely due to the small and superficial of the specimen. Therefore, as in this case, surgical specimens are conducive to diagnosis. The differential diagnosis should include other pleural spindle cell tumors, such as sarcomatous mesothelioma, primary pleural lymphoma, and sarcomatoid carcinoma, etc. Differential diagnosis also includes metastatic disease of pleural from synovial sarcoma elsewhere.
As the differential diagnosis is often challenging, immunohistochemistry is indispensable in confirming the diagnosis. For example, CD99 and B-cell lymphoma 2(BCL-2) are always positive in synovial sarcoma while negative in malignant mesothelioma [8]. Other positive immunohistochemical markers include keratin AE1/AE3, vimentin and actin, and negative markers include CD34, SMA and desmin [7][8][9].The chromosomal translocation t(X;18) (p11.2; q11.2), which can be detected by the fluorescence in situ hybridization occurs in more than 95% of patients, is also an important diagnostic tool [3,7]. However, this cytogenetic characteristic is not essential for diagnosis. In the present case, cytogenetic analysis was not performed.

Volume 29-Issue 1
The best treatment for PPSS remains unclear. A multidisciplinary approach, including surgery, chemotherapy and radiotherapy, can be beneficial according to the limited case reports. Because of its rarity, the evidence-based suggestions for treatment is lacking.
Synovial sarcomas are generally considered to be sensitive to certain chemotherapy drugs, such as ifosfamide and doxorubicin [7]. While no guidelines or consensus are available on the role of the chemotherapy on PPSS. Moreover, tyrosine kinase inhibitors pazopanib is approved for the treatment of soft tissue sarcomas and there are clinical trials and case report that suggest it may prolong survival [3,6]. Synovial sarcomas are biologically aggressive with a high incidence of recurrence and metastatic potential [3]. Prognosis of PPSS is usually poor with a 5-year survival rates range from 50% to 75% [7]. The prognosis may be associated with age, gender, tumor size, site and grade, complete resection or not, and response to chemotherapy, etc. [3,7].